Literature DB >> 25971378

Diffuse alveolar damage in nonresolving ARDS provides support for prolonged glucocorticoid treatment.

Gianfranco Umberto Meduri1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25971378     DOI： 10.1007/s00134-015-3797-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.

Authors:  Kenneth P Steinberg; Leonard D Hudson; Richard B Goodman; Catherine Lee Hough; Paul N Lanken; Robert Hyzy; B Taylor Thompson; Marek Ancukiewicz
Journal:  N Engl J Med       Date:  2006-04-20       Impact factor: 91.245

Review 2.  Understanding ARDS-associated fibroproliferation.

Authors:  Gianfranco Umberto Meduri; Mahmoud A Eltorky
Journal:  Intensive Care Med       Date:  2015-01-08       Impact factor: 17.440

3.  Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids.

Authors:  G Umberto Meduri; Elizabeth A Tolley; George P Chrousos; Frankie Stentz
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

4.  Open lung biopsy in nonresolving ARDS frequently identifies diffuse alveolar damage regardless of the severity stage and may have implications for patient management.

Authors:  Claude Guerin; Frédérique Bayle; Véronique Leray; Sophie Debord; Alina Stoian; Hodane Yonis; Jean-Baptiste Roudaut; Gael Bourdin; Mojgan Devouassoux-Shisheboran; Elodie Bucher; Louis Ayzac; Sylvie Lantuejoul; Carole Philipponnet; Jean Louis Kemeny; Bertrand Souweine; Jean-Christophe Richard
Journal:  Intensive Care Med       Date:  2014-12-05       Impact factor: 17.440

5.  Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies.

Authors:  Arnaud W Thille; Andrés Esteban; Pilar Fernández-Segoviano; José-María Rodriguez; José-Antonio Aramburu; Patricio Vargas-Errázuriz; Ana Martín-Pellicer; José A Lorente; Fernando Frutos-Vivar
Journal:  Lancet Respir Med       Date:  2013-05-15       Impact factor: 30.700

Review 6.  Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis.

Authors:  Benjamin M P Tang; Jonathan C Craig; Guy D Eslick; Ian Seppelt; Anthony S McLean
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

7.  Low-dose dexamethasone alleviates lipopolysaccharide-induced acute lung injury in rats and upregulates pulmonary glucocorticoid receptors.

Authors:  Xiao-Qiu Wang; Xin Zhou; Yan Zhou; Ling Rong; Lei Gao; Wei Xu
Journal:  Respirology       Date:  2008-07-24       Impact factor: 6.424

Review 8.  Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy.

Authors:  G Umberto Meduri; Djillali Annane; George P Chrousos; Paul E Marik; Scott E Sinclair
Journal:  Chest       Date:  2009-10-03       Impact factor: 9.410

9.  Steroid treatment for persistent ARDS: a word of caution.

Authors:  B Taylor Thompson; Marek Ancukiewicz; Leonard D Hudson; Kenneth P Steinberg; Gordon R Bernard
Journal:  Crit Care       Date:  2007       Impact factor: 9.097
  9 in total
  2 in total

1.  DAD in nonresolving ARDS provides support for prolonged glucocorticoid treatment: a rebuttal.

Authors:  Claude Guerin
Journal:  Intensive Care Med       Date:  2015-04-25       Impact factor: 17.440

2.  Effective and Safe Use of Glucocorticosteroids for Rescue of Late ARDS.

Authors:  Paolo Diana; Dustin T Money; Michael G Gelvin; Nadia Lunardi
Journal:  Case Rep Crit Care       Date:  2017-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.